Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells

Logan, IR, McClurg, UL ORCID: 0000-0003-2631-4174, Jones, DL, O'Neill, DJ, Shaheen, FS, Lunec, J, Gaughan, L and Robson, CN (2016) Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells Oncotarget, 7 (46). pp. 74724-74733. ISSN 1949-2553, 1949-2553

Text Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells.pdf - Author Accepted Manuscript Download (2MB)

Abstract

Inhibition of androgen receptor (AR) signalling represents the conventional medical management of prostate cancer. Ultimately this treatment fails because tumors develop an incurable, castrate resistant phenotype, resulting in an unmet need for new treatments in prostate cancer. The AR remains a viable therapeutic target in castrate resistant disease, such that novel ways of downregulating AR activities are attractive as potential treatments. Here we describe a mechanism by which the AR can be downregulated by the MDM2 antagonist Nutlin-3, resulting in loss of prosurvival c-FLIP gene expression and apoptosis. We additionally show that loss of c-FLIP sensitises prostate cancer cells to Nutlin-3. Finally, we demonstrate that the unrelated MDM2 antagonist Mi-63 also impinges upon AR signalling, supporting the concept of future treatment of prostate cancer with MDM2 antagonists.

Item Type:	Article
Uncontrolled Keywords:	prostate cancer, MDM2, androgen receptor, c-FLIP, anti-androgens
Depositing User:	Symplectic Admin
Date Deposited:	06 Nov 2018 12:47
Last Modified:	01 Mar 2026 04:53
DOI:	10.18632/oncotarget.12542
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3028465
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.